Rathin Gosavi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rathin Gosavi has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Vignesh Narasimhan
Department of Colorectal Surgery Monash Health Australia
16 shared publications William Teoh
12 shared publicationsPaul McMurrick
Department of Colorectal Surgery Cabrini Health Melbourne Victoria Australia
11 shared publicationsVignesh Narasimhan
9 shared publicationsSatish K. Warrier
Division of Cancer Surgery, Division of Cancer Research Peter MacCallum Cancer Centre Melbourne Victoria Australia
6 shared publicationsRaymond Yap
Department of Colorectal Surgery Cabrini Hospital Melbourne Victoria Australia
5 shared publications
Latest Publications
- 4 September 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Single-dose Preoperative Glucocorticoids in Major Gastrointestinal Surgery
Objective: To evaluate the clinical efficacy and safety of single-dose preoperative systemic glucocorticoids in adults undergoing major gastrointestinal surgery. Summary of Background Data: Major gastrointestinal surgery induces a systemic inflammatory response that contributes to postoperative morbidity and delayed recovery. Single-dose glucocorticoids attenuate inflammation, but uncertainty remains regarding clinical benefit, safety, and optimal dosing. Methods: A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials was performed and registered with PROSPERO. Trials comparing a single preoperative systemic glucocorticoid with placebo or no steroid in adult major gastrointestinal surgery were included. Primary outcomes were total postoperative complications and infectious complications. Secondary outcomes included length of stay, anastomotic leak, postoperative day 1 inflammatory markers, and mortality. Random-effects models were used. Dose-stratified analyses were prespecified and exploratory. Results: Eighteen randomized trials, including 3667 patients were analyzed. Preoperative glucocorticoids reduced total postoperative complications (OR 0.69, 95% CI: 0.54–0.89; I²=12%) and infectious complications (OR 0.62, 95% CI: 0.45–0.88; I²=55%). Length of stay was reduced by 1.09 days (95% CI: −1.68 to −0.50). Postoperative day 1 IL-6 was lower with glucocorticoids, while CRP showed no consistent difference. Anastomotic leak and mortality were not increased. Exploratory analyses suggested greater benefit with higher-dose regimens. Conclusions: Single-dose preoperative systemic glucocorticoids reduce postoperative morbidity, infections, and length of stay after major gastrointestinal surgery, without evidence of increased surgical harm in included trial populations.
- 4 September 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Single-dose Preoperative Glucocorticoids in Major Gastrointestinal Surgery
Objective: To evaluate the clinical efficacy and safety of single-dose preoperative systemic glucocorticoids in adults undergoing major gastrointestinal surgery. Summary of Background Data: Major gastrointestinal surgery induces a systemic inflammatory response that contributes to postoperative morbidity and delayed recovery. Single-dose glucocorticoids attenuate inflammation, but uncertainty remains regarding clinical benefit, safety, and optimal dosing. Methods: A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials was performed and registered with PROSPERO. Trials comparing a single preoperative systemic glucocorticoid with placebo or no steroid in adult major gastrointestinal surgery were included. Primary outcomes were total postoperative complications and infectious complications. Secondary outcomes included length of stay, anastomotic leak, postoperative day 1 inflammatory markers, and mortality. Random-effects models were used. Dose-stratified analyses were prespecified and exploratory. Results: Eighteen randomized trials, including 3667 patients were analyzed. Preoperative glucocorticoids reduced total postoperative complications (OR 0.69, 95% CI: 0.54–0.89; I²=12%) and infectious complications (OR 0.62, 95% CI: 0.45–0.88; I²=55%). Length of stay was reduced by 1.09 days (95% CI: −1.68 to −0.50). Postoperative day 1 IL-6 was lower with glucocorticoids, while CRP showed no consistent difference. Anastomotic leak and mortality were not increased. Exploratory analyses suggested greater benefit with higher-dose regimens. Conclusions: Single-dose preoperative systemic glucocorticoids reduce postoperative morbidity, infections, and length of stay after major gastrointestinal surgery, without evidence of increased surgical harm in included trial populations.
- Open Access
- 11 August 2026
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1) , 812
Bedside assistant models in robotic abdominal and pelvic surgery: a systematic review of operative efficiency, training exposure, and perioperative safety
Robotic surgery depends on effective bedside assistance, yet staffing models vary between physician and non-physician assistants. We systematically reviewed comparative evidence evaluating these models in robotic abdominal and pelvic surgery. A PRISMA compliant systematic review was performed. PubMed, Embase, Ovid MEDLINE, Cochrane CENTRAL/CCTR and ClinicalTrials.gov were searched from inception to 12 April 2026. Comparative adult clinical studies were eligible if they directly compared physician bedside assistance with non-physician bedside assistance during robot-assisted abdominal or pelvic surgery. The primary outcome domain was operative efficiency. Training exposure and perioperative safety were secondary domains. Risk of bias was assessed using ROBINS-I. Meta-analysis was not performed because of clinical and outcome heterogeneity. The search identified 1587 records, with 4 additional records from other sources. After duplicate removal, 693 records were screened and 22 full texts assessed; 3 observational studies met inclusion criteria. These included colorectal, gynaecologic oncology, and transplant/hepatopancreatobiliary robotic settings. Across studies, non-physician or dedicated bedside assistance was associated with favourable time-based efficiency outcomes, including shorter operative or console time in selected procedures and improved operational metrics in a dedicated team model. Training exposure was inconsistently reported, although one programme-level study found increased fellow primary surgeon participation after implementation of a dedicated robotic team. Safety outcomes did not show an obvious harm signal, but reporting was heterogeneous and studies were subject to confounding. Direct comparative evidence evaluating physician versus non-physician bedside assistant models in robotic abdominal and pelvic surgery is limited. Available data suggest possible efficiency benefits without an evident safety penalty, but stronger prospective studies with standardised efficiency, training and safety outcomes are needed.
- 11 August 2026
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1) , 812
Open AccessBedside assistant models in robotic abdominal and pelvic surgery: a systematic review of operative efficiency, training exposure, and perioperative safety
Robotic surgery depends on effective bedside assistance, yet staffing models vary between physician and non-physician assistants. We systematically reviewed comparative evidence evaluating these models in robotic abdominal and pelvic surgery. A PRISMA compliant systematic review was performed. PubMed, Embase, Ovid MEDLINE, Cochrane CENTRAL/CCTR and ClinicalTrials.gov were searched from inception to 12 April 2026. Comparative adult clinical studies were eligible if they directly compared physician bedside assistance with non-physician bedside assistance during robot-assisted abdominal or pelvic surgery. The primary outcome domain was operative efficiency. Training exposure and perioperative safety were secondary domains. Risk of bias was assessed using ROBINS-I. Meta-analysis was not performed because of clinical and outcome heterogeneity. The search identified 1587 records, with 4 additional records from other sources. After duplicate removal, 693 records were screened and 22 full texts assessed; 3 observational studies met inclusion criteria. These included colorectal, gynaecologic oncology, and transplant/hepatopancreatobiliary robotic settings. Across studies, non-physician or dedicated bedside assistance was associated with favourable time-based efficiency outcomes, including shorter operative or console time in selected procedures and improved operational metrics in a dedicated team model. Training exposure was inconsistently reported, although one programme-level study found increased fellow primary surgeon participation after implementation of a dedicated robotic team. Safety outcomes did not show an obvious harm signal, but reporting was heterogeneous and studies were subject to confounding. Direct comparative evidence evaluating physician versus non-physician bedside assistant models in robotic abdominal and pelvic surgery is limited. Available data suggest possible efficiency benefits without an evident safety penalty, but stronger prospective studies with standardised efficiency, training and safety outcomes are needed.
- Open Access
- 10 August 2026
- Published by Wiley in Anz Journal of Surgery
Seeing the Plane: Video Review as a Tool to Improve Total Mesorectal Excision Training
- 10 August 2026
- Published by Wiley in Anz Journal of Surgery
Open AccessSeeing the Plane: Video Review as a Tool to Improve Total Mesorectal Excision Training
- Open Access
- 9 August 2026
- Published by Wiley in Anz Journal of Surgery
The Evolving Landscape of Rectal Cancer Management—A Case for Centralisation?
- 9 August 2026
- Published by Wiley in Anz Journal of Surgery
Open AccessThe Evolving Landscape of Rectal Cancer Management—A Case for Centralisation?
- 23 June 2026
- Published by The Korean Association of Hepato-Biliary-Pancreatic Surgery in Annals of Hepato-Biliary-Pancreatic Surgery
- Vol. 30 (3) , 271-275
Resect first in resectable colorectal liver metastases: recalibrating the default
Perioperative chemotherapy is frequently used for resectable colorectal liver metastases (CRLM), despite persistent uncertainty regarding the extent of its survival benefit. This perspective revisits the evidence supporting this practice and asks whether upfront liver-directed treatment should be more strongly considered in selected patients. A central paradox underpins this debate: although adjuvant chemotherapy improves OS in stage III colon cancer, randomized trials in resectable CRLM have consistently failed to demonstrate an OS advantage for perioperative or adjuvant systemic therapy. Instead, chemotherapy primarily appears to delay recurrence while exposing patients to potential harms. These harms include treatment-related hepatic injury, increased perioperative morbidity, and, in some cases, progression during induction therapy that may preclude curative resection. Several explanations may account for this discrepancy, including clonal selection of resistant disease, the influence of the hepatic metastatic microenvironment, and the availability of salvage local therapy at recurrence. Nevertheless, systemic therapy remains relevant in selected patients with technically or biologically complex disease, such as those requiring staged liver surgery, downsizing for resectability, or treatment sequencing in synchronous primary and liver disease. Additionally, thermal ablation is emerging as a valid early liver-directed option for carefully selected small-volume metastases. Looking forward, circulating tumor DNA and other molecular tools may better identify the subgroup most likely to benefit from perioperative treatment. Treatment sequencing in resectable CRLM should therefore be guided by anatomy, tumour biology, and emerging molecular markers of residual risk, with systemic therapy used selectively rather than as a universal default.
- 23 June 2026
- Published by The Korean Association of Hepato-Biliary-Pancreatic Surgery in Annals of Hepato-Biliary-Pancreatic Surgery
- Vol. 30 (3) , 271-275
Resect first in resectable colorectal liver metastases: recalibrating the default
Perioperative chemotherapy is frequently used for resectable colorectal liver metastases (CRLM), despite persistent uncertainty regarding the extent of its survival benefit. This perspective revisits the evidence supporting this practice and asks whether upfront liver-directed treatment should be more strongly considered in selected patients. A central paradox underpins this debate: although adjuvant chemotherapy improves OS in stage III colon cancer, randomized trials in resectable CRLM have consistently failed to demonstrate an OS advantage for perioperative or adjuvant systemic therapy. Instead, chemotherapy primarily appears to delay recurrence while exposing patients to potential harms. These harms include treatment-related hepatic injury, increased perioperative morbidity, and, in some cases, progression during induction therapy that may preclude curative resection. Several explanations may account for this discrepancy, including clonal selection of resistant disease, the influence of the hepatic metastatic microenvironment, and the availability of salvage local therapy at recurrence. Nevertheless, systemic therapy remains relevant in selected patients with technically or biologically complex disease, such as those requiring staged liver surgery, downsizing for resectability, or treatment sequencing in synchronous primary and liver disease. Additionally, thermal ablation is emerging as a valid early liver-directed option for carefully selected small-volume metastases. Looking forward, circulating tumor DNA and other molecular tools may better identify the subgroup most likely to benefit from perioperative treatment. Treatment sequencing in resectable CRLM should therefore be guided by anatomy, tumour biology, and emerging molecular markers of residual risk, with systemic therapy used selectively rather than as a universal default.
- Open Access
- 29 May 2026
- Published by S. Karger AG in Digestive Diseases
- p. 1-10
Early-onset colorectal cancer in Australia: environmental, microbial, and policy implications
Background: Early-onset colorectal cancer (EOCRC; age <50 years) is rising in Australia despite improving outcomes in older adults. EOCRC shows a strong birth-cohort effect, disproportionate growth in left-sided and rectal tumours, and more frequent stage III–IV presentation. Most cases occur without a family history, indicating that environmental and biological pressures are accelerating carcinogenesis in otherwise average-risk hosts. Objective: To summarise current evidence on EOCRC aetiology, emphasising microbial, dietary and chemical exposures, and to outline clinical, policy and research priorities for Australia. Discussion: Traditional risks such as obesity, metabolic syndrome, sedentary behaviour, alcohol and smoking likely contribute via insulin resistance, chronic inflammation and IGF-1–mediated signalling, but they do not fully explain the recent acceleration or distal predominance. Hereditary syndromes account for a minority of EOCRC, and tumour driver mutation patterns broadly resemble later-onset colorectal cancer, supporting earlier triggering rather than novel genetics. Convergent evidence implicates gut dysbiosis and exposures that disrupt mucosal defences or cause direct DNA damage. Colibactin-producing Escherichia coli can induce a distinctive mutational signature that appears enriched in early and distal tumours. Microplastics and plasticisers may impair barrier function and promote low-grade inflammation, while PFAS and related endocrine-disrupting chemicals are linked to metabolic and immune perturbation and altered bile acid biology. Cumulative antibiotic exposure, particularly early in life, may reduce microbial diversity and favour pathobionts such as Fusobacterium nucleatum.
- 29 May 2026
- Published by S. Karger AG in Digestive Diseases
- p. 1-10
Open AccessEarly-onset colorectal cancer in Australia: environmental, microbial, and policy implications
Background: Early-onset colorectal cancer (EOCRC; age <50 years) is rising in Australia despite improving outcomes in older adults. EOCRC shows a strong birth-cohort effect, disproportionate growth in left-sided and rectal tumours, and more frequent stage III–IV presentation. Most cases occur without a family history, indicating that environmental and biological pressures are accelerating carcinogenesis in otherwise average-risk hosts. Objective: To summarise current evidence on EOCRC aetiology, emphasising microbial, dietary and chemical exposures, and to outline clinical, policy and research priorities for Australia. Discussion: Traditional risks such as obesity, metabolic syndrome, sedentary behaviour, alcohol and smoking likely contribute via insulin resistance, chronic inflammation and IGF-1–mediated signalling, but they do not fully explain the recent acceleration or distal predominance. Hereditary syndromes account for a minority of EOCRC, and tumour driver mutation patterns broadly resemble later-onset colorectal cancer, supporting earlier triggering rather than novel genetics. Convergent evidence implicates gut dysbiosis and exposures that disrupt mucosal defences or cause direct DNA damage. Colibactin-producing Escherichia coli can induce a distinctive mutational signature that appears enriched in early and distal tumours. Microplastics and plasticisers may impair barrier function and promote low-grade inflammation, while PFAS and related endocrine-disrupting chemicals are linked to metabolic and immune perturbation and altered bile acid biology. Cumulative antibiotic exposure, particularly early in life, may reduce microbial diversity and favour pathobionts such as Fusobacterium nucleatum.
- Open Access
- 28 April 2026
- Published by S. Karger AG in Digestive Surgery
- p. 1-5
Interval Appendicectomy after Conservative Management of Complicated Appendicitis: Balancing Recurrence, Neoplasm Risk, and Surveillance Strategies
Background: Non-operative management (NOM) of complicated appendicitis is increasingly accepted, but the role of interval appendicectomy (IA) remains contentious. Contemporary evidence has shifted decision-making from recurrence risk alone toward age-linked neoplasm risk and radiological features. Summary: Recurrence after successful NOM is commonly reported at 12–24% and is concentrated within the first 6 months. In adults presenting with periappendiceal abscess, appendiceal tumour prevalence rises with age, reaching approximately 5–10% in patients aged 35–39 years and 14–20% in cohorts aged ≥40 years. Interval CT or MRI findings, including dilated or cystic morphology, mural abnormalities, calcification, mucin, or a base mass, identify higher risk patients in whom IA should be prioritised. Colonoscopy is best used selectively, particularly when caecal pathology is suspected, imaging is equivocal, or IA is not planned in older patients. Key Messages: IA should generally be considered in patients aged ≥40 years and in those with persistent symptoms or concerning radiological findings, while recognising that decisions must be individualised and made through shared decision-making. Younger patients with complete radiological resolution and no red-flag features can usually be observed with structured imaging follow-up. A risk-stratified clinical algorithm is proposed to guide post-NOM management.
- 28 April 2026
- Published by S. Karger AG in Digestive Surgery
- p. 1-5
Open AccessInterval Appendicectomy after Conservative Management of Complicated Appendicitis: Balancing Recurrence, Neoplasm Risk, and Surveillance Strategies
Background: Non-operative management (NOM) of complicated appendicitis is increasingly accepted, but the role of interval appendicectomy (IA) remains contentious. Contemporary evidence has shifted decision-making from recurrence risk alone toward age-linked neoplasm risk and radiological features. Summary: Recurrence after successful NOM is commonly reported at 12–24% and is concentrated within the first 6 months. In adults presenting with periappendiceal abscess, appendiceal tumour prevalence rises with age, reaching approximately 5–10% in patients aged 35–39 years and 14–20% in cohorts aged ≥40 years. Interval CT or MRI findings, including dilated or cystic morphology, mural abnormalities, calcification, mucin, or a base mass, identify higher risk patients in whom IA should be prioritised. Colonoscopy is best used selectively, particularly when caecal pathology is suspected, imaging is equivocal, or IA is not planned in older patients. Key Messages: IA should generally be considered in patients aged ≥40 years and in those with persistent symptoms or concerning radiological findings, while recognising that decisions must be individualised and made through shared decision-making. Younger patients with complete radiological resolution and no red-flag features can usually be observed with structured imaging follow-up. A risk-stratified clinical algorithm is proposed to guide post-NOM management.
- Open Access
- 16 April 2026
- Published by Wiley in Anz Journal of Surgery
- Vol. 96 (9) , 2270-2273
Parastomal Hernia: Rethinking Prevention and Repair in Contemporary Colorectal Surgery
- 16 April 2026
- Published by Wiley in Anz Journal of Surgery
- Vol. 96 (9) , 2270-2273
Open AccessParastomal Hernia: Rethinking Prevention and Repair in Contemporary Colorectal Surgery
- Open Access
- 10 April 2026
- Published by Wiley in Anz Journal of Surgery
- Vol. 96 (7-8) , 1818-1821
Training for Rectal Resection in the Era of Total Neoadjuvant Therapy and Organ Preservation: Safeguarding Competence as Operative Casemix Evolves
- 10 April 2026
- Published by Wiley in Anz Journal of Surgery
- Vol. 96 (7-8) , 1818-1821
Open AccessTraining for Rectal Resection in the Era of Total Neoadjuvant Therapy and Organ Preservation: Safeguarding Competence as Operative Casemix Evolves
- Open Access
- 9 February 2026
- Published by Springer Nature in Hernia
- Vol. 30 (1) , 90
Parastomal hernia prevention and repair in Australasia: A binational CSSANZ survey of contemporary practice
Background: Parastomal hernia (PSH) is a debilitating long-term complication of stoma formation, often required as part of curative or palliative treatment for colorectal cancer. As a common downstream consequence of cancer surgery, PSH contributes significantly to chronic morbidity and impairs quality of life, yet practices surrounding its prevention and repair remain heterogeneous. Despite randomised evidence supporting prophylactic mesh, adoption is limited, and operative approaches to elective and emergency repair vary widely. Methods: A cross-sectional survey of colorectal surgeons in Australia and New Zealand was conducted via the Colorectal Surgical Society of Australia and New Zealand (CSSANZ) to assess current PSH management. The survey examined stoma creation practices, prophylactic and therapeutic mesh use, operative techniques, and responses to clinical vignettes. Subgroup analyses explored variation by surgeon seniority, practice setting, and country. Results: Ninety-three surgeons responded (93/365, 25.5%), including 74/93 (79.6%) from Australia and 19/93 (20.4%) from New Zealand; 79/93 (84.9%) practised in metropolitan centres and 39/93 (41.9%) had > 15 years’ experience. Routine prophylactic mesh use at stoma formation was reported by 11/93 (11.8%). For elective repair (n = 89), open access was preferred by 48/89 (53.9%) and Sugarbaker repair was the most common configuration (40/89, 44.9%). Technique selection differed by access: among surgeons favouring minimally invasive surgery (n = 41), 33/41 (80.5%) selected Sugarbaker, whereas those favouring open surgery (n = 48) more often selected keyhole (22/48, 45.8%) or retrorectus “sandwich” repair (18/48, 37.5%) (p < 0.00001). In the emergency small-bowel obstruction vignette, surgeons with > 15 years’ experience more often favoured mesh use than those with ≤ 15 years (21/39, 53.8% vs 10/50, 20.0%; p = 0.0015). Overall operative volume was low, with 65/93 (69.9%) reporting 0–5 PSH repairs per year. Conclusions: PSH prevention and repair across Australasia is marked by wide variability, low uptake of prophylactic mesh, and inconsistent technique selection. Operative approach strongly influenced repair configuration, and seniority appeared to drive emergency decision-making. Addressing PSH represents an important opportunity to reduce treatment-related morbidity in patients with pelvic malignancies undergoing stoma formation.
- 9 February 2026
- Published by Springer Nature in Hernia
- Vol. 30 (1) , 90
Open AccessParastomal hernia prevention and repair in Australasia: A binational CSSANZ survey of contemporary practice
Background: Parastomal hernia (PSH) is a debilitating long-term complication of stoma formation, often required as part of curative or palliative treatment for colorectal cancer. As a common downstream consequence of cancer surgery, PSH contributes significantly to chronic morbidity and impairs quality of life, yet practices surrounding its prevention and repair remain heterogeneous. Despite randomised evidence supporting prophylactic mesh, adoption is limited, and operative approaches to elective and emergency repair vary widely. Methods: A cross-sectional survey of colorectal surgeons in Australia and New Zealand was conducted via the Colorectal Surgical Society of Australia and New Zealand (CSSANZ) to assess current PSH management. The survey examined stoma creation practices, prophylactic and therapeutic mesh use, operative techniques, and responses to clinical vignettes. Subgroup analyses explored variation by surgeon seniority, practice setting, and country. Results: Ninety-three surgeons responded (93/365, 25.5%), including 74/93 (79.6%) from Australia and 19/93 (20.4%) from New Zealand; 79/93 (84.9%) practised in metropolitan centres and 39/93 (41.9%) had > 15 years’ experience. Routine prophylactic mesh use at stoma formation was reported by 11/93 (11.8%). For elective repair (n = 89), open access was preferred by 48/89 (53.9%) and Sugarbaker repair was the most common configuration (40/89, 44.9%). Technique selection differed by access: among surgeons favouring minimally invasive surgery (n = 41), 33/41 (80.5%) selected Sugarbaker, whereas those favouring open surgery (n = 48) more often selected keyhole (22/48, 45.8%) or retrorectus “sandwich” repair (18/48, 37.5%) (p < 0.00001). In the emergency small-bowel obstruction vignette, surgeons with > 15 years’ experience more often favoured mesh use than those with ≤ 15 years (21/39, 53.8% vs 10/50, 20.0%; p = 0.0015). Overall operative volume was low, with 65/93 (69.9%) reporting 0–5 PSH repairs per year. Conclusions: PSH prevention and repair across Australasia is marked by wide variability, low uptake of prophylactic mesh, and inconsistent technique selection. Operative approach strongly influenced repair configuration, and seniority appeared to drive emergency decision-making. Addressing PSH represents an important opportunity to reduce treatment-related morbidity in patients with pelvic malignancies undergoing stoma formation.